The share of Russian-made medical devices reached 20%. For the drugs, it is already almost 32%; and in physical terms, 69%. Moreover, this level was achieved in all key segments of the pharmaceutical market, including 7 nosologies, medications for the treatment of oncological diseases, and the drugs for the treatment of HIV infection.
“For the products included in the list of vital and essential drugs (VED), we are significantly ahead of target indicators and, today, the share of domestic medicines is already 83%. Next year, we want to reach the level of 90% for Russian-made medicines,” said the Minister of Industry and Trade of the Russian Federation Denis Manturov.
These results were achieved by creating the most favorable environment for the development of Russian manufacturers. For example, 19 new pharmaceutical production facilities were opened since 2013. The comprehensive state support provided at all stages of the life cycle, from preclinical studies to demand stimulation, was also effective.
The world’s largest manufacturers of the industry built 7 plants in Russia; and another 78 foreign companies localized their manufacturing at the facilities of Russian enterprises. In 6 years, the total investments in the industry reached more than 150 billion rubles.
62 Russian medicines were registered since 2009; 18 of them are being launched in this year alone.
“Growing exports are yet another sign that we are on the right track; in the first half of 2017 alone, they increased by 23.5%,” said Denis Manturov.
He added that, today, there are good conditions for the development of innovative pharmaceutical and medical industry, and competencies in the area of biotechnology.
This is illustrated by the approval of up-to-date bio-target list for the development of innovative medicines. Promising areas include complex protein and synthetic products, drugs based on monoclonal antibodies, and nanobio systems for drug delivery.